Namita Thapar’s current investment in Emcure Pharmaceuticals Limited grew by a massive 38,200% to ₹671 crore – following the company’s 31% listing premium on the NSE.

Emcure Pharmaceuticals’ ₹1,952 Cr IPO received 67.87 times subscription on the final day of the offer on Friday.

In 2007, after her MBA and a successful stint at a US medical device company – Namita returned to India to join her family business, Emcure, as the CFO and was soon appointed as the Executive Director.

In 2021, the company reported a profit of Rs 418 crore on a revenue of Rs 6091 crore!

In addition to Emcure, Thapar leads Incredible Ventures Ltd, an education company that teaches entrepreneurship to 11 to 18-year-olds.

Credit - Inc42 Media